Lundh H, Nilsson O, Rosén I
J Neurol Neurosurg Psychiatry. 1979 Feb;42(2):171-5. doi: 10.1136/jnnp.42.2.171.
A new drug, 4-aminopyridine, was prepared for use in humans and tested by repeated injections in six patients with myasthenia gravis. The drug caused improvement of muscle strength and neuromuscular transmission as demonstrated by clinical observations and repetitive electrical nerve stimulation. The drug was effective in cases without any other treatment as well as in cases undergoing treatment with anticholinesterases. It is concluded that 4-aminopyridine may be of value as a supplementary drug in the treatment of myasthenia gravis.
一种名为4-氨基吡啶的新药被制备用于人体，并在6例重症肌无力患者身上进行了重复注射测试。临床观察和重复神经电刺激表明，该药物可改善肌肉力量和神经肌肉传递。该药物在未接受任何其他治疗的病例以及接受抗胆碱酯酶治疗的病例中均有效。得出结论，4-氨基吡啶作为重症肌无力治疗的辅助药物可能具有价值。
